<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02112838</url>
  </required_header>
  <id_info>
    <org_study_id>C-935788-050</org_study_id>
    <secondary_id>2014-000331-16</secondary_id>
    <nct_id>NCT02112838</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy</brief_title>
  <official_title>A Phase 2, Multi-Center, Randomised, Double-Blind, Ascending-Dose, Placebo-Controlled Clinical Study to Assess the Safety and Efficacy of Fostamatinib in the Treatment of IgA Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rigel Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rigel Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether fostamatinib is safe and effective in the
      treatment of IgA Nephropathy
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">November 12, 2018</completion_date>
  <primary_completion_date type="Actual">March 23, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change of Proteinuria as Measured by Spot Urine Protein/Creatinine Ratio (sPCR) at Week 24</measure>
    <time_frame>Baseline to 24 weeks</time_frame>
    <description>Mean change from Baseline (Visit 2) of proteinuria as measured by the spot Protein-Creatinine Ratio (sPCR) at 24 weeks (Visit 9) for the ITT Population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Pre-treatment to Post-treatment in Mesangial Hypercellularity (M) on Renal Biopsies.</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Mean change from pre-treatment to post-treatment in mesangial hypercellularity on renal biopsies. Using the Oxford Classification of IgA Nepthropathy (IgAN), biopsy specimens with a minimum of 8 glomeruli, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), and interstitial fibrosis/tubular atrophy (T) lesions are scored for assessing histologic findings in IgAN.
M = the mean score based on Oxford Classification system score is based on total count of mesangial cells for all glomeruli (count of &lt;4=0 score, 4 to 5=1, 6 to 7=2, ≥8=3). A decrease in score equates to improvement from IgAN disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With ≥50% Reduction in sPCR From Baseline (Visit 2) at Week 24 (Visit 9).</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Percentage of subjects with ≥50% reduction in sPCR from Baseline (Visit 2) at Week 24 (Visit 9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With ≥ 30% Reduction in Proteinuria From Baseline (Visit 2) at 24 Weeks (Visit 9).</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Percentage of subjects with ≥ 30% reduction in proteinuria from Baseline (Visit 2) at 24 weeks (Visit 9).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Endocapillary Hypercellularity (E) on Renal Biopsies.</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Mean change from pre-treatment to post-treatment in mesangial hypercellularity on renal biopsies. Using the Oxford Classification of IgA Nepthropathy (IgAN), biopsy specimens with a minimum of 8 glomeruli, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), and interstitial fibrosis/tubular atrophy (T) lesions are scored for assessing histologic findings in IgAN.
E = Percentage of glomeruli eypercellularity due to increased number of cells within glomerular capillary lumina causing narrowing of the lumina. A decrease in score equates to improvement from IgAN disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Segmental Sclerosis/Adhesion (S) on Renal Biopsies.</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Mean change from pre-treatment to post-treatment in mesangial hypercellularity on renal biopsies. Using the Oxford Classification of IgA Nepthropathy (IgAN), biopsy specimens with a minimum of 8 glomeruli, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), and interstitial fibrosis/tubular atrophy (T) lesions are scored for assessing histologic findings in IgAN.
S = Percentage of any amount of the tuft involved in sclerosis, but not involving the whole tuft or the presence of an adhesion in each glomeruli. A decrease in score equates to improvement from IgAN disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Global Glomerulosclerosis Score on Renal Biopsies.</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Mean change from pre-treatment to post-treatment in mesangial hypercellularity on renal biopsies. Using the Oxford Classification of IgA Nepthropathy (IgAN), biopsy specimens with a minimum of 8 glomeruli, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), and interstitial fibrosis/tubular atrophy (T) lesions are scored for assessing histologic findings in IgAN.
Percentage of any amount of the tuft involved in sclerosis, but not involving the whole tuft or the presence of an adhesion in each glomeruli. A decrease in score equates to improvement from IgAN disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Tubulointerstitial Scarring (T) on Renal Biopsies.</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Mean change from pre-treatment to post-treatment in mesangial hypercellularity on renal biopsies. Using the Oxford Classification of IgA Nepthropathy (IgAN), biopsy specimens with a minimum of 8 glomeruli, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), and interstitial fibrosis/tubular atrophy (T) lesions are scored for assessing histologic findings in IgAN.
T= Percentage of cortical area involved by the tubular atrophy or interstitial fibrosis, whichever is greater. A decrease in score equates to improvement from IgAN disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Cellular/Fibrocellular Crescent Score on Renal Biopsies.</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Mean change from pre-treatment to post-treatment in cellular/fibrocellular crescent score on renal biopsies. Biopsy specimens with a minimum of 8 glomeruli, mesangial hypercellularity (M), segmental sclerosis (S), and interstitial fibrosis/tubular atrophy (T) lesions are scored using the Oxford Classification of IgA nepthropathy (IgAN) system for assessing histologic findings in IgAN.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline (Visit 2) of eGFR at 12 Weeks (Visit 7).</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Mean change from Baseline (Visit 2) of eGFR at 12 weeks (Visit 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline (Visit 2) of eGFR at 24 Weeks (Visit 9).</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Mean change from Baseline (Visit 2) of eGFR at 24 weeks (Visit 9).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline (Visit 2) of Proteinuria at 12 Weeks (Visit 7).</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Mean change from Baseline (Visit 2) of proteinuria at 12 weeks (Visit 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects With sPCR &lt;50 mg/mmol (500 mg/g) at 12 Weeks (Visit 7).</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Percentage of subjects with sPCR &lt;50 mg/mmol (500 mg/g) at 12 weeks (Visit 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shift in Haematuria (Dipstick Test) From Baseline (Visit 2) at 12 Weeks (Visit 7).</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Shift in haematuria (dipstick test) from Baseline (Visit 2) at 12 weeks (Visit 7).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shift in Haematuria (Dipstick Test) From Baseline (Visit 2) at 24 Weeks (Visit 9).</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Shift in haematuria (dipstick test) from Baseline (Visit 2) at 24 weeks (Visit 9).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">76</enrollment>
  <condition>IGA Nephropathy</condition>
  <arm_group>
    <arm_group_label>Fostamatinib 150 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fostamatinib 100 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib 150 mg</intervention_name>
    <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
    <arm_group_label>Fostamatinib 150 mg</arm_group_label>
    <other_name>R935788</other_name>
    <other_name>R788</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fostamatinib 100 mg</intervention_name>
    <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
    <arm_group_label>Fostamatinib 100 mg</arm_group_label>
    <other_name>R935788</other_name>
    <other_name>R788</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal biopsy findings consistent with IgA nephropathy

          -  Treatment with an Angiotensin Converting Enzyme inhibitor (ACEi) and/or an Angiotensin
             II Receptor Blocker (ARB) for at least 90 days at the maximum approved (or tolerated)
             dose

          -  Proteinuria &gt; 1 gm/day at diagnosis of IgA nephropathy and Proteinuria &gt; 0.50 gm/day
             at the second Screening Visit

          -  Blood pressure controlled to ≤ 130/80 with angiotensin blockade with or without other
             anti-hypertensive agents

        Exclusion Criteria:

          -  Recent use of cyclophosphamide, mycophenolate mofetil, azathioprine, or Rituximab.

          -  Use of &gt; 15 mg/day prednisone (or other corticosteroid equivalent).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rigel Pharmaceuticals, Inc.</last_name>
    <role>Study Director</role>
    <affiliation>Rigel Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Medical</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nephrology Associates PC, University Hospital, Professional Center 1</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southeast Renal Research Institute</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Graz</name>
      <address>
        <city>Graz</city>
        <state>Steiermark</state>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna, Nephrology</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wurtemberberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität München</name>
      <address>
        <city>Munich</city>
        <state>Bayern</state>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>1307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of Jena</name>
      <address>
        <city>Jena</city>
        <state>Thueringen</state>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <state>Sha Tin</state>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>40447</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>School of Medicine, Chang Gung University, Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Addenbrookes Hospital</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiff University</name>
      <address>
        <city>Cardiff</city>
        <zip>CF14 4XN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester General Hospital</name>
      <address>
        <city>Leicester</city>
        <zip>LE5 4PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Free Hospital</name>
      <address>
        <city>London</city>
        <zip>NW3 2PF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hammersmith Hospital</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE7 7DN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Taiwan</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Singapore</country>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>April 10, 2014</study_first_submitted>
  <study_first_submitted_qc>April 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 14, 2014</study_first_posted>
  <results_first_submitted>March 21, 2019</results_first_submitted>
  <results_first_submitted_qc>June 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 27, 2019</results_first_posted>
  <last_update_submitted>June 10, 2019</last_update_submitted>
  <last_update_submitted_qc>June 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IGA Glomerulonephritis</keyword>
  <keyword>Nephritis, IGA Type</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Glomerulonephritis, IGA</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 17, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT02112838/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT02112838/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fostamatinib 150 mg</title>
          <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 150 mg: Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
        </group>
        <group group_id="P2">
          <title>Fostamatinib 100 mg</title>
          <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 100 mg: Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo tablet twice daily by mouth, over the course of 24 weeks
Placebo: Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>the 76 subjects who were randomized and received at least 1 dose of the blinded study drug comprised the ITT Population, the Safety Population, and the PK Population. Paired biopsies with &gt;8 scoreable glomeruli were available from 27 subjects who constituted the Biopsy Population.</population>
      <group_list>
        <group group_id="B1">
          <title>Fostamatinib 150 mg</title>
          <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 150 mg: Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
        </group>
        <group group_id="B2">
          <title>Fostamatinib 100 mg</title>
          <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 100 mg: Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo tablet twice daily by mouth, over the course of 24 weeks
Placebo: Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="76"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.1" spread="14.8"/>
                    <measurement group_id="B2" value="42.3" spread="14.1"/>
                    <measurement group_id="B3" value="40.6" spread="11.6"/>
                    <measurement group_id="B4" value="42.0" spread="40.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Not collected</measurement>
                    <measurement group_id="B2" value="NA">Not collected</measurement>
                    <measurement group_id="B3" value="NA">Not collected</measurement>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Not collected</measurement>
                    <measurement group_id="B2" value="NA">Not collected</measurement>
                    <measurement group_id="B3" value="NA">Not collected</measurement>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="51"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Not collected</measurement>
                    <measurement group_id="B2" value="NA">Not collected</measurement>
                    <measurement group_id="B3" value="NA">Not collected</measurement>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Not collected</measurement>
                    <measurement group_id="B2" value="NA">Not collected</measurement>
                    <measurement group_id="B3" value="NA">Not collected</measurement>
                    <measurement group_id="B4" value="NA">Total not calculated because data are not available (NA) in one or more arms.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Change of Proteinuria as Measured by Spot Urine Protein/Creatinine Ratio (sPCR) at Week 24</title>
        <description>Mean change from Baseline (Visit 2) of proteinuria as measured by the spot Protein-Creatinine Ratio (sPCR) at 24 weeks (Visit 9) for the ITT Population</description>
        <time_frame>Baseline to 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 150 mg</title>
            <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 150 mg: Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 100 mg</title>
            <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 100 mg: Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet twice daily by mouth, over the course of 24 weeks
Placebo: Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change of Proteinuria as Measured by Spot Urine Protein/Creatinine Ratio (sPCR) at Week 24</title>
          <description>Mean change from Baseline (Visit 2) of proteinuria as measured by the spot Protein-Creatinine Ratio (sPCR) at 24 weeks (Visit 9) for the ITT Population</description>
          <units>mg/g</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-157.5" spread="345.6"/>
                    <measurement group_id="O2" value="-577.2" spread="335.7"/>
                    <measurement group_id="O3" value="-177.4" spread="342.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>19.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-910.6</ci_lower_limit>
            <ci_upper_limit>950.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.40</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-399.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1320.8</ci_lower_limit>
            <ci_upper_limit>521.3</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Pre-treatment to Post-treatment in Mesangial Hypercellularity (M) on Renal Biopsies.</title>
        <description>Mean change from pre-treatment to post-treatment in mesangial hypercellularity on renal biopsies. Using the Oxford Classification of IgA Nepthropathy (IgAN), biopsy specimens with a minimum of 8 glomeruli, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), and interstitial fibrosis/tubular atrophy (T) lesions are scored for assessing histologic findings in IgAN.
M = the mean score based on Oxford Classification system score is based on total count of mesangial cells for all glomeruli (count of &lt;4=0 score, 4 to 5=1, 6 to 7=2, ≥8=3). A decrease in score equates to improvement from IgAN disease.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Analysis population includes only subjects with both pre-treatment and post-treatment biopsies collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 150 mg</title>
            <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 150 mg: Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 100 mg</title>
            <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 100 mg: Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet twice daily by mouth, over the course of 24 weeks
Placebo: Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Pre-treatment to Post-treatment in Mesangial Hypercellularity (M) on Renal Biopsies.</title>
          <description>Mean change from pre-treatment to post-treatment in mesangial hypercellularity on renal biopsies. Using the Oxford Classification of IgA Nepthropathy (IgAN), biopsy specimens with a minimum of 8 glomeruli, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), and interstitial fibrosis/tubular atrophy (T) lesions are scored for assessing histologic findings in IgAN.
M = the mean score based on Oxford Classification system score is based on total count of mesangial cells for all glomeruli (count of &lt;4=0 score, 4 to 5=1, 6 to 7=2, ≥8=3). A decrease in score equates to improvement from IgAN disease.</description>
          <population>Analysis population includes only subjects with both pre-treatment and post-treatment biopsies collected.</population>
          <units>mesangial hypercellularity score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>renal biopsy samples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>renal biopsy samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="1.6"/>
                    <measurement group_id="O2" value="-0.2" spread="0.1"/>
                    <measurement group_id="O3" value="-0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With ≥50% Reduction in sPCR From Baseline (Visit 2) at Week 24 (Visit 9).</title>
        <description>Percentage of subjects with ≥50% reduction in sPCR from Baseline (Visit 2) at Week 24 (Visit 9)</description>
        <time_frame>Baseline to Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 150 mg</title>
            <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 150 mg: Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 100 mg</title>
            <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 100 mg: Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet twice daily by mouth, over the course of 24 weeks
Placebo: Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With ≥50% Reduction in sPCR From Baseline (Visit 2) at Week 24 (Visit 9).</title>
          <description>Percentage of subjects with ≥50% reduction in sPCR from Baseline (Visit 2) at Week 24 (Visit 9)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With ≥ 30% Reduction in Proteinuria From Baseline (Visit 2) at 24 Weeks (Visit 9).</title>
        <description>Percentage of subjects with ≥ 30% reduction in proteinuria from Baseline (Visit 2) at 24 weeks (Visit 9).</description>
        <time_frame>Baseline to Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 150 mg</title>
            <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 150 mg: Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 100 mg</title>
            <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 100 mg: Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet twice daily by mouth, over the course of 24 weeks
Placebo: Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With ≥ 30% Reduction in Proteinuria From Baseline (Visit 2) at 24 Weeks (Visit 9).</title>
          <description>Percentage of subjects with ≥ 30% reduction in proteinuria from Baseline (Visit 2) at 24 weeks (Visit 9).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Endocapillary Hypercellularity (E) on Renal Biopsies.</title>
        <description>Mean change from pre-treatment to post-treatment in mesangial hypercellularity on renal biopsies. Using the Oxford Classification of IgA Nepthropathy (IgAN), biopsy specimens with a minimum of 8 glomeruli, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), and interstitial fibrosis/tubular atrophy (T) lesions are scored for assessing histologic findings in IgAN.
E = Percentage of glomeruli eypercellularity due to increased number of cells within glomerular capillary lumina causing narrowing of the lumina. A decrease in score equates to improvement from IgAN disease.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Analysis population includes only subjects with both pre-treatment and post-treatment biopsies collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 150 mg</title>
            <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 150 mg: Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 100 mg</title>
            <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 100 mg: Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet twice daily by mouth, over the course of 24 weeks
Placebo: Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Endocapillary Hypercellularity (E) on Renal Biopsies.</title>
          <description>Mean change from pre-treatment to post-treatment in mesangial hypercellularity on renal biopsies. Using the Oxford Classification of IgA Nepthropathy (IgAN), biopsy specimens with a minimum of 8 glomeruli, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), and interstitial fibrosis/tubular atrophy (T) lesions are scored for assessing histologic findings in IgAN.
E = Percentage of glomeruli eypercellularity due to increased number of cells within glomerular capillary lumina causing narrowing of the lumina. A decrease in score equates to improvement from IgAN disease.</description>
          <population>Analysis population includes only subjects with both pre-treatment and post-treatment biopsies collected.</population>
          <units>Percentage of glomeruli</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>renal biopsy samples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>renal biopsy samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.1" spread="3.2"/>
                    <measurement group_id="O2" value="-4.0" spread="1.5"/>
                    <measurement group_id="O3" value="-5.4" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Segmental Sclerosis/Adhesion (S) on Renal Biopsies.</title>
        <description>Mean change from pre-treatment to post-treatment in mesangial hypercellularity on renal biopsies. Using the Oxford Classification of IgA Nepthropathy (IgAN), biopsy specimens with a minimum of 8 glomeruli, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), and interstitial fibrosis/tubular atrophy (T) lesions are scored for assessing histologic findings in IgAN.
S = Percentage of any amount of the tuft involved in sclerosis, but not involving the whole tuft or the presence of an adhesion in each glomeruli. A decrease in score equates to improvement from IgAN disease.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Analysis population includes only subjects with both pre-treatment and post-treatment biopsies collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 150 mg</title>
            <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 150 mg: Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 100 mg</title>
            <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 100 mg: Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet twice daily by mouth, over the course of 24 weeks
Placebo: Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Segmental Sclerosis/Adhesion (S) on Renal Biopsies.</title>
          <description>Mean change from pre-treatment to post-treatment in mesangial hypercellularity on renal biopsies. Using the Oxford Classification of IgA Nepthropathy (IgAN), biopsy specimens with a minimum of 8 glomeruli, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), and interstitial fibrosis/tubular atrophy (T) lesions are scored for assessing histologic findings in IgAN.
S = Percentage of any amount of the tuft involved in sclerosis, but not involving the whole tuft or the presence of an adhesion in each glomeruli. A decrease in score equates to improvement from IgAN disease.</description>
          <population>Analysis population includes only subjects with both pre-treatment and post-treatment biopsies collected.</population>
          <units>Percentage of glomeruli</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>renal biopsy samples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>renal biopsy samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="7.8"/>
                    <measurement group_id="O2" value="-6.8" spread="3.6"/>
                    <measurement group_id="O3" value="-0.8" spread="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Global Glomerulosclerosis Score on Renal Biopsies.</title>
        <description>Mean change from pre-treatment to post-treatment in mesangial hypercellularity on renal biopsies. Using the Oxford Classification of IgA Nepthropathy (IgAN), biopsy specimens with a minimum of 8 glomeruli, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), and interstitial fibrosis/tubular atrophy (T) lesions are scored for assessing histologic findings in IgAN.
Percentage of any amount of the tuft involved in sclerosis, but not involving the whole tuft or the presence of an adhesion in each glomeruli. A decrease in score equates to improvement from IgAN disease.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Analysis population includes only subjects with both pre-treatment and post-treatment biopsies collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 150 mg</title>
            <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 150 mg: Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 100 mg</title>
            <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 100 mg: Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet twice daily by mouth, over the course of 24 weeks
Placebo: Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Global Glomerulosclerosis Score on Renal Biopsies.</title>
          <description>Mean change from pre-treatment to post-treatment in mesangial hypercellularity on renal biopsies. Using the Oxford Classification of IgA Nepthropathy (IgAN), biopsy specimens with a minimum of 8 glomeruli, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), and interstitial fibrosis/tubular atrophy (T) lesions are scored for assessing histologic findings in IgAN.
Percentage of any amount of the tuft involved in sclerosis, but not involving the whole tuft or the presence of an adhesion in each glomeruli. A decrease in score equates to improvement from IgAN disease.</description>
          <population>Analysis population includes only subjects with both pre-treatment and post-treatment biopsies collected.</population>
          <units>Percentage of glomeruli</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>renal biopsy samples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>renal biopsy samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.9" spread="10.1"/>
                    <measurement group_id="O2" value="8.34" spread="4.8"/>
                    <measurement group_id="O3" value="0.5" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Tubulointerstitial Scarring (T) on Renal Biopsies.</title>
        <description>Mean change from pre-treatment to post-treatment in mesangial hypercellularity on renal biopsies. Using the Oxford Classification of IgA Nepthropathy (IgAN), biopsy specimens with a minimum of 8 glomeruli, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), and interstitial fibrosis/tubular atrophy (T) lesions are scored for assessing histologic findings in IgAN.
T= Percentage of cortical area involved by the tubular atrophy or interstitial fibrosis, whichever is greater. A decrease in score equates to improvement from IgAN disease.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Analysis population includes only subjects with both pre-treatment and post-treatment biopsies collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 150 mg</title>
            <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 150 mg: Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 100 mg</title>
            <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 100 mg: Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet twice daily by mouth, over the course of 24 weeks
Placebo: Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Tubulointerstitial Scarring (T) on Renal Biopsies.</title>
          <description>Mean change from pre-treatment to post-treatment in mesangial hypercellularity on renal biopsies. Using the Oxford Classification of IgA Nepthropathy (IgAN), biopsy specimens with a minimum of 8 glomeruli, mesangial hypercellularity (M), endocapillary hypercellularity (E), segmental sclerosis (S), and interstitial fibrosis/tubular atrophy (T) lesions are scored for assessing histologic findings in IgAN.
T= Percentage of cortical area involved by the tubular atrophy or interstitial fibrosis, whichever is greater. A decrease in score equates to improvement from IgAN disease.</description>
          <population>Analysis population includes only subjects with both pre-treatment and post-treatment biopsies collected.</population>
          <units>Percentage of glomeruli</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>renal biopsy samples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>renal biopsy samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.4" spread="9.7"/>
                    <measurement group_id="O2" value="4.4" spread="4.6"/>
                    <measurement group_id="O3" value="-1.7" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Cellular/Fibrocellular Crescent Score on Renal Biopsies.</title>
        <description>Mean change from pre-treatment to post-treatment in cellular/fibrocellular crescent score on renal biopsies. Biopsy specimens with a minimum of 8 glomeruli, mesangial hypercellularity (M), segmental sclerosis (S), and interstitial fibrosis/tubular atrophy (T) lesions are scored using the Oxford Classification of IgA nepthropathy (IgAN) system for assessing histologic findings in IgAN.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Analysis population includes only subjects with both pre-treatment and post-treatment biopsies collected.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 150 mg</title>
            <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 150 mg: Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 100 mg</title>
            <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 100 mg: Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet twice daily by mouth, over the course of 24 weeks
Placebo: Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Pre-treatment to Post-treatment in Percentage of Glomeruli With Cellular/Fibrocellular Crescent Score on Renal Biopsies.</title>
          <description>Mean change from pre-treatment to post-treatment in cellular/fibrocellular crescent score on renal biopsies. Biopsy specimens with a minimum of 8 glomeruli, mesangial hypercellularity (M), segmental sclerosis (S), and interstitial fibrosis/tubular atrophy (T) lesions are scored using the Oxford Classification of IgA nepthropathy (IgAN) system for assessing histologic findings in IgAN.</description>
          <population>Analysis population includes only subjects with both pre-treatment and post-treatment biopsies collected.</population>
          <units>Percentage of glomeruli</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <units_analyzed>renal biopsy samples</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>renal biopsy samples</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="1.6"/>
                    <measurement group_id="O2" value="-1.5" spread="0.8"/>
                    <measurement group_id="O3" value="-0.4" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline (Visit 2) of eGFR at 12 Weeks (Visit 7).</title>
        <description>Mean change from Baseline (Visit 2) of eGFR at 12 weeks (Visit 7).</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Analysis population includes only subjects who completed visits through Week 12.</population>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 150 mg</title>
            <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 150 mg: Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 100 mg</title>
            <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 100 mg: Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet twice daily by mouth, over the course of 24 weeks
Placebo: Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline (Visit 2) of eGFR at 12 Weeks (Visit 7).</title>
          <description>Mean change from Baseline (Visit 2) of eGFR at 12 weeks (Visit 7).</description>
          <population>Analysis population includes only subjects who completed visits through Week 12.</population>
          <units>eGFR (mL/min/1.73 m2)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="25"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0" spread="2.1"/>
                    <measurement group_id="O2" value="2.1" spread="1.9"/>
                    <measurement group_id="O3" value="1.4" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline (Visit 2) of eGFR at 24 Weeks (Visit 9).</title>
        <description>Mean change from Baseline (Visit 2) of eGFR at 24 weeks (Visit 9).</description>
        <time_frame>Baseline to Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 150 mg</title>
            <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 150 mg: Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 100 mg</title>
            <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 100 mg: Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet twice daily by mouth, over the course of 24 weeks
Placebo: Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline (Visit 2) of eGFR at 24 Weeks (Visit 9).</title>
          <description>Mean change from Baseline (Visit 2) of eGFR at 24 weeks (Visit 9).</description>
          <units>eGFR (mL/min/1.73 m2)</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.9" spread="1.9"/>
                    <measurement group_id="O2" value="2.0" spread="1.8"/>
                    <measurement group_id="O3" value="-0.2" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline (Visit 2) of Proteinuria at 12 Weeks (Visit 7).</title>
        <description>Mean change from Baseline (Visit 2) of proteinuria at 12 weeks (Visit 7).</description>
        <time_frame>Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 150 mg</title>
            <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 150 mg: Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 100 mg</title>
            <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 100 mg: Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet twice daily by mouth, over the course of 24 weeks
Placebo: Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline (Visit 2) of Proteinuria at 12 Weeks (Visit 7).</title>
          <description>Mean change from Baseline (Visit 2) of proteinuria at 12 weeks (Visit 7).</description>
          <units>mg/g</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-293.1" spread="202.0"/>
                    <measurement group_id="O2" value="-529.2" spread="196.4"/>
                    <measurement group_id="O3" value="-328.3" spread="199.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects With sPCR &lt;50 mg/mmol (500 mg/g) at 12 Weeks (Visit 7).</title>
        <description>Percentage of subjects with sPCR &lt;50 mg/mmol (500 mg/g) at 12 weeks (Visit 7).</description>
        <time_frame>Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 150 mg</title>
            <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 150 mg: Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 100 mg</title>
            <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 100 mg: Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet twice daily by mouth, over the course of 24 weeks
Placebo: Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects With sPCR &lt;50 mg/mmol (500 mg/g) at 12 Weeks (Visit 7).</title>
          <description>Percentage of subjects with sPCR &lt;50 mg/mmol (500 mg/g) at 12 weeks (Visit 7).</description>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Shift in Haematuria (Dipstick Test) From Baseline (Visit 2) at 12 Weeks (Visit 7).</title>
        <description>Shift in haematuria (dipstick test) from Baseline (Visit 2) at 12 weeks (Visit 7).</description>
        <time_frame>Baseline to Week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 150 mg</title>
            <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 150 mg: Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 100 mg</title>
            <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 100 mg: Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet twice daily by mouth, over the course of 24 weeks
Placebo: Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Shift in Haematuria (Dipstick Test) From Baseline (Visit 2) at 12 Weeks (Visit 7).</title>
          <description>Shift in haematuria (dipstick test) from Baseline (Visit 2) at 12 weeks (Visit 7).</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Same/Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Shift in Haematuria (Dipstick Test) From Baseline (Visit 2) at 24 Weeks (Visit 9).</title>
        <description>Shift in haematuria (dipstick test) from Baseline (Visit 2) at 24 weeks (Visit 9).</description>
        <time_frame>Baseline to Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fostamatinib 150 mg</title>
            <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 150 mg: Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O2">
            <title>Fostamatinib 100 mg</title>
            <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 100 mg: Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo tablet twice daily by mouth, over the course of 24 weeks
Placebo: Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Shift in Haematuria (Dipstick Test) From Baseline (Visit 2) at 24 Weeks (Visit 9).</title>
          <description>Shift in haematuria (dipstick test) from Baseline (Visit 2) at 24 weeks (Visit 9).</description>
          <units>subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Increased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Same/Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>The AE reporting period begins with the first dose of study drug and ends with the final study (follow-up) visit. AEs that occur between the time of consent and first dose of study drug will be reported as Medical History. If an SAE is present at the follow-up visit (Week 26, Visit 10) or final visit for subjects receiving extended treatment it was followed to resolution or stabilization unless the subject is lost to follow-up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fostamatinib 150 mg</title>
          <description>Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 150 mg: Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks</description>
        </group>
        <group group_id="E2">
          <title>Fostamatinib 100 mg</title>
          <description>Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
Fostamatinib 100 mg: Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo tablet twice daily by mouth, over the course of 24 weeks
Placebo: Placebo tablet twice daily by mouth, over the course of 24 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Peptic Ulcer Perforation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Post Procedural Haematuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic Enzyme Abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sandra Tong</name_or_title>
      <organization>Rigel Pharmaceuticals</organization>
      <phone>1-650-624-1207</phone>
      <email>stong@rigel.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

